Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for endothelial dysfunction after hip fracture
ACTRN12609000278235Phase 4Withdrawn
- Sponsor
- Gustavo Duque
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of zoledronic acid in endothelial dysfunction and osteoporosis (2 arms), sponsored by Gustavo Duque. Primary endpoint: Changes in markers of endothelial dysfunction. Planned start Jun 2009; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
endothelial dysfunctionosteoporosis
Beyond the preview
Go deeper on ACTRN12609000278235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000278235.